To elucidate the mechanisms of neuroprotective action of nicergoline, we examined its effect on glutamate transport in rat cortical synaptosomes and cloned glutamate transporters. In synaptosomes, nicergoline enhanced the glutamate uptake at 1-10 m mM in standard medium and suppressed the increase of extracellular glutamate by reversed transport in low Na ؉ medium. Apparent increase of extracellular glutamate concentration by dihydrokinate, an inhibitor of glial glutamate transporter GLT-1, was antagonized by nicergoline. In Xenopus oocytes expressing mouse neuronal glutamate transporter (mEAAC1), the glutamate-induced inward current was enhanced by nicergoline. These results suggest that nicergoline reduces the extracellular glutamate concentration through its effect on glutamate transporters.
Glutamate transporters limit the extracellular concentration of glutamate ([Glu] o ) utilizing Na
ϩ electrochemical gradient as a driving force. Under physiological conditions, released glutamate in the synaptic cleft is transported into intracellular space by the glutamate transporters. [1] [2] [3] [4] [5] [6] [7] [8] Substantial loss of glutamate uptake activity has been reported in some chronic neurodegenerative disorders including amyotrophic lateral sclerosis 9) and Alzheimer's disease. 10, 11) When the intracellular Na ϩ milieu is disturbed upon cerebral ischemia, the transporter functions in a reverse direction to release glutamate to neurotoxic levels. 1, [12] [13] [14] Therefore, controlling the function of glutamate transporter is a potential therapeutic strategy for neuronal diseases. 15) Nicergoline, a derivative of ergot alkaloid, is an ameliorator of cerebral circulation and metabolism. [16] [17] [18] [19] [20] [21] [22] [23] [24] In addition to enhancement of cholinergic [25] [26] [27] [28] and dopaminergic transmissions in the brain, 29) protective actions of nicergoline against anoxic and/or ischemic brain damage and neuronal cell death are reported in several cerebral ischemic animals. [18] [19] [20] 30) A recent study showed the neuroprotective action and the reduction of [Glu] o by nicergoline in ischemic rat brains. 31) Another ergort alkaloid, bromocriptine, was shown to enhance the glutamate transport activity. 11) In order to examine the effects of drugs on the uptake and reversed transport mediated by glutamate transporters, we previously developed an assay system in which extracellular glutamate concentration was measured in the synaptosome preparation. 32) In the present study, in order to understand the mechanisms of action of nicergoline to reduce [Glu] o , we examined its effect on the glutamate transport activity in rat cortical synaptosomes as well as on cloned glutamate transporters.
MATERIALS AND METHODS

Animals
All experiments were performed in accordance with the regulations of the Animal Ethics Committee of TANABE Seiyaku Co., Ltd. Male Wistar strain rats weighing 200-400 g were used for preparation of crude synaptosomal fractions. Xenopus laevis (20-30 months old) were used for preparation of oocytes.
Synaptosomal Preparation Crude synaptosomal fractions were prepared following the standard procedures. 33) Rats were anesthetized with ether, and whole brains were removed after decapitation. The cerebral cortex, isolated under an ice-cold condition, was homogenized in a 5-fold volume of 0.32 M sucrose. The homogenate was centrifuged at 1500ϫg for 10 min, and the supernatant was centrifuged at 9000ϫg for 20 min. The pellet (P2 fraction) was suspended in 0.32 M sucrose solution again and centrifuged at 9000ϫg for 20 min. The above procedures were carried out at 4°C. The pellet was resuspended in 0.32 M sucrose, and used as a crude synaptosome preparation in the following experiments after determining the protein content. Protein content of the crude synaptosome preparation was 5.71Ϯ0.18 mg/ml (meanϮS.E., nϭ15). This preparation contained not only intra-synaptosomal glutamate, but also a small amount of extracellular glutamate. The glutamate in the synaptosomal preparation was of intrinsic origin.
Determination of Extracellular Glutamate in Synaptosomal Preparation Glutamate transporters mediate the uptake and the reversed transport of glutamate depending on both the electrochemical gradient of co-transported Na ϩ /counter-transported K ϩ and the temperature. 34) Synaptosomes were incubated at 37°C in standard HEPES buffered saline (HBS) medium containing 140.0 mM NaCl, 5 mM KCl, 5.0 mM NaHCO 3 , 1 mM MgCl 2 , 0.12 mM Na 2 SO 4 , 10 mM glucose, and 20 mM HEPES (pH 7.4). Fifty microliters of the crude synaptosome preparation was added to 1 ml of HBS or low Na ϩ medium prepared by substituting Na ϩ with choline. The synaptosomes in each medium with or without drugs were kept on ice until the start of the reaction. After incubation at 37°C for up to 6 min, the transport reaction was terminated by immediately transferring the incubation tube into an ice-cold water bath. Then, the synaptosomes were centrifuged at 9000ϫg for 20 min at 4°C, and the supernatants were stocked at Ϫ80°C until the measurement of glutamate contents. The concentration of glutamate in the supernatants was determined using the glutamate dehydrogenase-NADP method.
35)
Xenopus Oocytes mRNA was in vitro transcribed from linearized pBluescript II SK (Ϫ) vector or pSP64poly(A) vector (Stratagene) containing the coding region of mEAAC1 (mouse EAAT-3) using T7 RNA polymerase (Stratagene). The Xenopus laevis oocytes were isolated by partial ovariectomy. After mild digestion with collagenase and defolliculation, oocytes were injected with cRNA solutions using a Drummond automatic injector Nanoject 203-VX (Drummond Scientific Company, U.S.A.). The injected volume was 50 nl/oocyte containing 30-80 ng of the cRNA. The oocytes were incubated at 18°C in ND 96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, 2.5 mM Na-pyruvate, 0.5 mM theophylline, pH 7.5 with NaOH) containing penicillin (100 U/ml), streptomycin (100 mg/ml) and gentamicin (50 mg/ml).
Electrophysiology Two to 10 days after injection, oocytes were immersed in a normal external solution (NES) containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.5, and analyzed using the two-microelectrode voltage-clamp method at room temperature (22-23°C). The microelectrodes were filled with a 3 M KCl solution, and their resistances were 0.5-2 MW. The membrane potential of an oocyte placed in a tissue chamber was clamped at Ϫ60 mV. Glutamate was applied to the bath, and the substrate-evoked inward current was recorded by a recording amplifier (GeneClamp 500, Axon Instruments Inc., U.S.A.). The effect of nicergoline was studied on the inward current induced by 10 mM glutamate in mEAAC1-expressing oocytes. The response of currents to a high concentration of glutamate (30 mM) was determined in each oocyte beforehand.
Chemicals The following materials were of reagent grade and obtained from commercial sources: HEPES (Nacalai Tesque Co., Ltd, Tokyo, Japan), glutamate dehydrogenase, NADP, collagenase, theophylline, penicillin, streptomycin, gentamicin (Sigma Chemicals Co., Ltd., St. Louis, MO, U.S.A.), dihydrokainic acid (DHK), bromocriptine (Tocris Cookson Inc., St. Louis, MO, U.S.A.). Nicergoline was provided by Pharmacia & Upjohn (Tokyo, Japan).
RESULTS
In synaptosome preparations, [Glu] (Fig. 1) . Namely, nicergoline enhanced the reduction of [Glu] (Fig. 1) . The reduction of [Glu] o by nicergoline in the standard HBS medium was concentration-dependent at doses between 1 and 10 mM. In contrast, the concentration-response relations in the low Na ϩ medium ([Na ϩ ] o ϭ16.4 mM) were statistically significant only at 1 mM, and formed a bell shaped curve (Fig. 2) . In the same preparations, bromocriptine, an ergot alkaloid, had not effect [Glu] o (Fig. 3) .
DHK, a selective inhibitor of glial glutamate transporter GLT-1, 32, 33) ] o ϭ16.4 mM). Nicergoline at 1 mM antagonized both effects of DHK (Fig. 4) .
In oocytes expressing mEAAC1, inward current was evoked by perfusion of glutamate in the recording chamber. , it is proposed that the reduction and the elevation mainly reflect the uptake into and reversed transport from synaptosomes, respectively. The uptake of glutamate by the transporters requires sufficient concentration of Na Both neuronal and glial transporters participate in the control of extracellular glutamate concentration.
[Glu] o was decreased due to the uptake by both transporters in the standard HBS medium. Because the intracellular concentration of glutamate is high (1 mM) in neurons, neuronal glutamate transporters are assumed to function in the reverse direction before glial transporters do when Na ϩ homeostasis is disrupted in brain ischemia or under anoxic conditions. DHK, a selective inhibitor of glial GLT-1 glutamate transporter, 36, 37) ϩ medium indicates the existence of uptake via glial glutamate transporter GLT-1 even under the low Na ϩ condition. The DHK-induced increase of [Glu] o is suppressed by nicergoline in both standard HBS and low Na ϩ media. Glutamate transporters work mainly in the forward direction (uptake) in the standard HBS medium and in the reverse direction in the low Na ϩ medium. The concentration-dependent effect of nicergoline was more pronounced in standard HBS medium than in low Na ϩ medium. However, there was no reduction of D [Glu] o by nicergoline at the lowest Na ϩ concentration. When Na ϩ concentration is 5.24 mM GLT-1 does not uptake extracellular glutamate. Thus, nicergoline reduces [Glu] o by enhancing the uptake rather than inhibiting the reversed transport of glutamate.
Bromocriptine was reported to enhance the uptake of glutamate by human GluT-1 15, 38) stably expressed in HeLaS3 cells. GluT-1 is a subtype of glutamate transporters expressed predominantly in cerebellum 39) among brain regions. We used synaptosome from rat cerebral cortex without cerebellum. In this study, bromocriptine failed to enhance the uptake of glutamate; this lack of effect may have been due to low abundance of GluT-1 in the preparation.
In order to further confirm the effect of nicergoline on glutamate transporters, we determined the effect on cloned neuronal transporter EAAC1. We used mouse EAAC1 that was 97% homologous at the amino acid level with rat EAAC1. Nicergoline increased the glutamate-induced current mediated by EAAC1. Although we also attempted to examine the effect of nicergoline on cloned glial transporter encoded by GLT-1, the glutamate-induced current mediated by GLT-1 was too small to make this evaluation. It has been reported that glutamate transporter is regulated by transporter-associated proteins. 40) Thus, inhibition of the function of the associating protein may result in the enhancement of the glutamate transport. Although the mechanisms behind the action of nicergoline remain unclear at this moment, it is possible that nicergoline acts on the transporter-associated protein to enhance the transport function.
In this study, we showed the enhancement of neuronal glutamate transport by nicergoline in both oocytes expressing mEAAC1 and synaptosomes in the presence of DHK. Although the function of EAAC1 was changed from uptake to reversed transport in lower Na ϩ condition, the uptake was enhanced by nicergoline except for the lowest Na ϩ concentration. Therefore, we propose that nicergoline acts on both glial and neuronal glutamate transporters.
Extracellular concentration of glutamate is crucial for the development of neuronal damage following ischemia. 1, [12] [13] [14] Enhancement of glutamate uptake by nicergoline may, at least in part, contribute to the reduction of glutamate concentration in the brain which results in ischemia. The synaptosome prepared from rat cerebral cortex includes at least two subtypes of glutamate transporters, EAAC1 and GLT-1. Human EAAC1 and human GLT-1 are 90% and 91% homologous at the amino acid level with rat EAAC1 and rat GLT-1, respectively. Thus it is reasonable to speculate that a similar Ϫ4 N) only slightly reduced the inward current. Nicergoline significantly increased the glutamate-induced inward current in a concentration-dependent manner (Fig. 5) .
effect of nicergoline can be expected in both rodents and humans.
The concentration of nicergoline in the central nervous system at a clinical dosage (15 mg/day) is expected to reach sub microM order, which is comparable to the effective concentration in the present study. Nicergoline reduces [Glu] o in the brain and protects brain damage by ischemia in rats. 31) Thus, the demonstration of transporter-modulating activity warrants consideration of a clinical neuroprotective effect of nicergoline.
